Pharma News

 

High-intensity exercise three times a week is safe for individuals with early-stage Parkinson's disease and decreases worsening of motor symptoms, according to a new phase 2, multi-site trial led by University of Colorado Anschutz Medical Campus and Northwestern Medicine scientists. This is the first time scientists have tested the effects [...]
Tue, Dec 12, 2017
Source Pharmanews
Boehringer Ingelheim
2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim's two-pronged research strategy - investigating both cancer cell-directed therapies and immune cell-directed [...]
Mon, Dec 11, 2017
Source Pharmanews
FDA
Today, the U.S. Food and Drug Administration announced an adult smoking cessation education campaign aimed at encouraging cigarette smokers to quit through messages of support that underscore the health benefits of quitting. These messages will be displayed in and around gas stations and convenience stores - retail locations where smokers [...]
Mon, Dec 11, 2017
Source Pharmanews
Novartis
Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws of France ("Purchaser"), has commenced a cash tender offer to purchase all of the outstanding ordinary shares, nominal value EUR 0.10 per share, including Ordinary Shares [...]
Thu, Dec 07, 2017
Source Pharmanews

 

(by Worldpharmanews)

Contact us
Medial D&P Ltd.
Gewerbestrasse 18
4123 Allschwil
Switzerland
Phone: +41 61 487 96 22
Fax. +41 61 487 96 20
medial@medialpharma.com